Skip to main content

Day: January 8, 2025

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA) MoonLake now independently running seven trials in 2025 across large dermatology and rheumatology indications: adult HS, adolescent HS, psoriatic arthritis (PsA), PPP and axSpA Phase 2 and Phase 3 data read-outs across all target indications expected in 2025 (adult HS, and PPP) and 2026 (adolescent HS, PsA and axSpA) Data from the Phase 3 VELA-TEEN trial may be combined with the Phase 3 VELA program in adults with moderate-to-severe HS to support the first Biologics License Application (BLA) for the Nanobody® sonelokimabZug, Switzerland, January 8, 2025 – MoonLake Immunotherapeutics...

Continue reading

EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology

AUSTIN, Texas, January 8, 2025 – EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored by the Centre Léon Bérard, Lyon, France, evaluating proprietary High Intensity Focused Ultrasound (HIFU) technology for the treatment of pancreatic tumors. “The initiation of the PULS Trial represents a major milestone in efforts to develop a new and innovative approach for treating this devastating disease with such poor prognosis,” said Professor Aurélien Dupré, MD, PhD, Surgical Oncologist, Centre Léon Bérard, and Principal Investigator of the PULS Trial. “For patients diagnosed with locally advanced pancreatic cancer, the standard treatment is chemotherapy with or without radiotherapy. The low proportion of patients who can...

Continue reading

ECARX’s Cloudpeak® Hypervisor Receives ISO 26262 ASIL-D Certification

SHANGHAI, Jan. 08, 2025 (GLOBE NEWSWIRE) — ECARX Holdings, Inc. (Nasdaq: ECX) (“ECARX” or “the Company”), a global mobility tech provider, today announced that its Cloudpeak® hypervisor, a core component of its Cloudpeak® software stack, received the highest level of functional safety certification, Automotive Safety Integrity Level (“ASIL”) D, under the ISO 26262 standard. The ASIL-D certification was jointly issued by LQRA and DEKRA, two internationally recognized independent third-party testing, inspection, and certification organizations, underscoring ECARX’s robust capabilities in automotive-grade safety development and management. The ASIL-D certification is a testament to ECARX’s unwavering commitment to safety and its long-term investment in developing efficient and safe intelligent solutions for automobiles. As automotive...

Continue reading

Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) — Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci’s advanced de novo antibody design models. AMD will also make a $20 million investment in Absci, structured as a private investment in public equity (PIPE), underscoring the growing demand for innovative AI applications in drug discovery. The strategic partnership supports Absci’s mission of creating better biologics for patients, faster...

Continue reading

Bitfarms to Present at Needham Growth Conference in NYC

TORONTO, Ontario and BROSSARD, Québec, Jan. 08, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq/TSX: BITF) (“Bitfarms”), a global vertically integrated Bitcoin data center company, will be attending Needham’s 27th Annual Growth Conference, taking place from January 14-15th in New York City. Bitfarms CEO Ben Gagnon, CFO Jeff Lucas, and SVP IR & Corp. Comms. Tracy Krumme will be conducting investor meetings with a presentation at the following time: Bitfarms Company PresentationDate: Wednesday, January 15thTime: 8:45-9:25am EasternPresenters: CEO Ben Gagnon and CFO Jeff LucasWebcast Link A replay of the webcast will be available on Bitfarms’ investor site. To sign up for 1×1 meetings at the conference, please contact your sales representative at Needham or email investors@bitfarms.com. About Bitfarms Ltd. Founded in 2017,...

Continue reading

BitFuFu Unveils BitFuFuOS Software Service to Boost Mining Revenue by up to 20%

SINGAPORE, Jan. 08, 2025 (GLOBE NEWSWIRE) — BitFuFu Inc., (“BitFuFu” or “the Company”) (NASDAQ: FUFU), a global leader in Bitcoin mining and comprehensive mining services, today announced the launch of its new software service, BitFuFuOS, which can increase mining overall earnings by up to 20%. By integrating miners, hosting, mining pools, and software services, BitFuFu aims to provide users with a seamless one-stop mining experience.BitFuFuOS website : https://www.bitfufu.com/FuFuMinerOS Designed for ease of use, advanced customization, and flexibility, BitFuFuOS features a range of overclocking and underclocking modes, empowering miners to optimize operations on the fly, based on temperature conditions, power availability and market conditions. BitFuFuOS aims to enhance miner performance, boost efficiency, and maximize profitability...

Continue reading

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab’s Potential in the Treatment of Neurological Disease

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a review article titled “Immune mechanisms and shared immune targets in neurodegenerative diseases” was published in Nature Reviews Neurology, highlighting the therapeutic potential of intranasal foralumab in various neurodegenerative diseases including Multiple Sclerosis (MS), Alzheimer’s disease, ALS, and Parkinsons disease. The immune system plays a significant role in neurodegenerative diseases. In some, such as multiple sclerosis, it is the primary driver of the disease. In others, such as Alzheimer’s disease, amyotrophic...

Continue reading

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. “I am pleased to welcome Dr. Sanders to EyePoint’s Board,” said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. “Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. Sanders will be an invaluable addition to our Board. With our global phase 3 pivotal trials for wet AMD underway and the recent positive interim...

Continue reading

Opthea to Host Investor Days in New York and Australia

Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on February 3 and Melbourne on February 5 MELBOURNE, Australia and PRINCETON, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it will host an Investor Day on Tuesday, January 28, 2025 at 1:30 PM ET in New York City, followed by presentations in Sydney and Melbourne in early February. As the Company prepares for the anticipated topline data readout of its two pivotal trials, COAST in early...

Continue reading

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company’s website at https://ir.ateapharma.com. An archived webcast will be available on Atea Pharmaceuticals’ website for at least 90 days following the event. About Atea Pharmaceuticals Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.